Literature DB >> 17845146

Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.

Serk In Park1, Ami N Shah, Jing Zhang, Gary E Gallick.   

Abstract

Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845146     DOI: 10.1517/14728222.11.9.1207

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  21 in total

1.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

2.  Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis.

Authors:  Venkaiah Betapudi; Meenal Shukla; Ravi Alluri; Sergei Merkulov; Keith R McCrae
Journal:  FASEB J       Date:  2016-07-11       Impact factor: 5.191

Review 3.  Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Martine Soell; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mosaad Megahed
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 4.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

5.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Authors:  Eric B Haura; Tawee Tanvetyanon; Alberto Chiappori; Charles Williams; George Simon; Scott Antonia; Jhanelle Gray; Sharon Litschauer; Leticia Tetteh; Anthony Neuger; Lanxi Song; Bhupendra Rawal; Michael J Schell; Gerold Bepler
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Src-signaling interference impairs the dissemination of blood-borne tumor cells.

Authors:  Dietmar W Siemann; Meiyu Dong; Chris Pampo; Wenyin Shi
Journal:  Cell Tissue Res       Date:  2012-04-18       Impact factor: 5.249

7.  MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer.

Authors:  Shahana Majid; Sharanjot Saini; Altaf A Dar; Hiroshi Hirata; Varahram Shahryari; Yuichiro Tanaka; Soichiro Yamamura; Koji Ueno; Mohd Saif Zaman; Kamaldeep Singh; Inik Chang; Guoren Deng; Rajvir Dahiya
Journal:  Cancer Res       Date:  2011-02-17       Impact factor: 12.701

Review 8.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion.

Authors:  Pavan Adiseshaiah; Michelle Vaz; Narsa Machireddy; Dhananjaya V Kalvakolanu; Sekhar P Reddy
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

10.  Redox-sensitive Akt and Src regulate coronary collateral growth in metabolic syndrome.

Authors:  Ryan Reed; Barry Potter; Erika Smith; Rashmi Jadhav; Patricia Villalta; Hanjoong Jo; Petra Rocic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-17       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.